Without a product Replicel reached $300 during it's bubble. It's Japanese partner Shiseido still angry in a frosty relationship with Replicel due to lack of delayed funding on REPCF's german trial - is now rumored to make an announcement 2018 using REPCF's IP. Shiseido and Replicel were involved in a deal years ago that concluded Shiseido owns the human population of Asia in regards to marketing and collecting royalties off this hair cloning technology in trade that both companies spend tens of millions of dollars on research and human trials. When Replicel failed to spend Shiseido threatened to sue. Now that the situation has settled the science remains to be showcased. Because it's already been tested. Human trials have been conducted the last 2 years. The company Shiseido is sitting on that data. Whether they are sitting on the biggest cosmetic market on the planet or not is in that data.
At a quick glance you can see the timeline and the run up in price. This technology has a head start in japan being autologous there is NO third phase clinical trial only phase 2.
Excellent long. 100,000 ROI set up. ($1,000 to $1,000,000) if this thing hits it's previous resistance from 12 years ago.
At a quick glance you can see the timeline and the run up in price. This technology has a head start in japan being autologous there is NO third phase clinical trial only phase 2.
Excellent long. 100,000 ROI set up. ($1,000 to $1,000,000) if this thing hits it's previous resistance from 12 years ago.